in Newswire Published on September 20, 2019

Class Action: Drug Makers Conspired to Overcharge for Diabetes Medication Glumetza [UPDATE]

by Erin Shaak

Last Updated on August 19, 2020

Meijer, Inc. et al. v. Bausch Health Companies Inc. et al.

Filed: September 18, 2019 § 3:19-cv-05822

A proposed class action lawsuit out of California claims the prices of type 2 diabetes medication Glumetza and its generic version have skyrocketed due to an anticompetitive conspiracy executed by the drugs’ manufacturers.

Case Updates

August 19, 2020 – Class of Direct Glumetza Buyers Certified by Calif. Judge

Update—October 1, 2019—Two More Class Actions Filed Over Allegedly Anticompetitive Glumetza Pricing Conspiracy

This browser does not support PDFs. Please download the PDF to view it: Download PDF.

Last Updated on August 19, 2020 — 3:10 PM

Erin Shaak

Erin works primarily on’s newswire, reporting on cases as they happen.

About is a group of online professionals (designers, developers and writers) with years of experience in the legal industry.

Learn More

Before commenting, please review our comment policy.